113 related articles for article (PubMed ID: 16601281)
1. Characterization of the functional and growth properties of long-term cell cultures established from a human somatostatinoma.
Galli G; Zonefrati R; Gozzini A; Mavilia C; Martineti V; Tognarini I; Nesi G; Marcucci T; Tonelli F; Tommasi M; Raggi CC; Pinzani P; Brandi ML
Endocr Relat Cancer; 2006 Mar; 13(1):79-93. PubMed ID: 16601281
[TBL] [Abstract][Full Text] [Related]
2. Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.
Ludvigsen E; Stridsberg M; Taylor JE; Culler MD; Oberg K; Janson ET
Med Oncol; 2004; 21(3):285-95. PubMed ID: 15456957
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro.
Ferone D; van Hagen MP; Kwekkeboom DJ; van Koetsveld PM; Mooy DM; Lichtenauer-Kaligis E; Schönbrunn A; Colao A; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2000 Apr; 85(4):1719-26. PubMed ID: 10770220
[TBL] [Abstract][Full Text] [Related]
5. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
Hofland LJ; van der Hoek J; Feelders R; van Aken MO; van Koetsveld PM; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; de Herder WW; Beckers A; Lamberts SW
Eur J Endocrinol; 2005 Apr; 152(4):645-54. PubMed ID: 15817922
[TBL] [Abstract][Full Text] [Related]
6. Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture.
Falchetti A; Franchi A; Bordi C; Mavilia C; Masi L; Cioppi F; Recenti R; Picariello L; Marini F; Del Monte F; Ghinoi V; Martineti V; Tanini A; Brandi ML
J Bone Miner Res; 2005 Mar; 20(3):410-8. PubMed ID: 15746985
[TBL] [Abstract][Full Text] [Related]
7. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
8. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient.
Resmini E; Dadati P; Ravetti JL; Zona G; Spaziante R; Saveanu A; Jaquet P; Culler MD; Bianchi F; Rebora A; Minuto F; Ferone D
J Clin Endocrinol Metab; 2007 May; 92(5):1592-9. PubMed ID: 17311860
[TBL] [Abstract][Full Text] [Related]
9. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
[TBL] [Abstract][Full Text] [Related]
10. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
[TBL] [Abstract][Full Text] [Related]
11. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment.
Froidevaux S; Hintermann E; Török M; Mäcke HR; Beglinger C; Eberle AN
Cancer Res; 1999 Aug; 59(15):3652-7. PubMed ID: 10446977
[TBL] [Abstract][Full Text] [Related]
12. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
13. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells.
Ferone D; van Hagen PM; van Koetsveld PM; Zuijderwijk J; Mooy DM; Lichtenauer-Kaligis EG; Colao A; Bogers AJ; Lombardi G; Lamberts SW; Hofland LJ
Endocrinology; 1999 Jan; 140(1):373-80. PubMed ID: 9886848
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro.
de Bruin C; Feelders RA; Waaijers AM; van Koetsveld PM; Sprij-Mooij DM; Lamberts SW; Hofland LJ
J Mol Endocrinol; 2009 Jan; 42(1):47-56. PubMed ID: 18852217
[TBL] [Abstract][Full Text] [Related]
16. 17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo.
Visser-Wisselaar HA; Van Uffelen CJ; Van Koetsveld PM; Lichtenauer-Kaligis EG; Waaijers AM; Uitterlinden P; Mooy DM; Lamberts SW; Hofland LJ
Endocrinology; 1997 Mar; 138(3):1180-9. PubMed ID: 9048625
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
Hubina E; Nanzer AM; Hanson MR; Ciccarelli E; Losa M; Gaia D; Papotti M; Terreni MR; Khalaf S; Jordan S; Czirják S; Hanzély Z; Nagy GM; Góth MI; Grossman AB; Korbonits M
Eur J Endocrinol; 2006 Aug; 155(2):371-9. PubMed ID: 16868153
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy.
Pasquali D; Vassallo P; Esposito D; Bonavolontà G; Bellastella A; Sinisi AA
J Mol Endocrinol; 2000 Aug; 25(1):63-71. PubMed ID: 10915219
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of pasireotide and octreotide on lymphocyte activation.
Lattuada D; Casnici C; Crotta K; Mastrotto C; Franco P; Schmid HA; Marelli O
J Neuroimmunol; 2007 Jan; 182(1-2):153-9. PubMed ID: 17113654
[TBL] [Abstract][Full Text] [Related]
20. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors.
Notas G; Kolios G; Mastrodimou N; Kampa M; Vasilaki A; Xidakis C; Castanas E; Thermos K; Kouroumalis E
J Hepatol; 2004 May; 40(5):792-8. PubMed ID: 15094227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
